Denali Therapeutics has received accelerated approval for AVLAYAH, validating its TransportVehicle platform and marking its move into commercial operations. Early payer coverage and positive Q3 guidance support a credible launch, though AVLAYAH's US label limits near-term growth. The company also has potential upside from upcoming 2027 data readouts for Zafinofusp alfa and other pipeline candidates. Despite inherent biotech risks, Denali's platform and future catalysts make it an interesting speculative investment at current levels.
Ripple Labs CEO Brad Garlinghouse stated the company is now more neutral about pursuing an IPO, after being private for a long time. Ripple aims to reach a $1 billion annualized revenue run rate by the end of 2026, excluding XRP sales, despite a bear...
VanadiumCorp Resource Inc. has completed a soil geochemical survey at its Lac Laura Gold-Copper Property in Quebec's Chibougamau Mining District, collecting 314 soil samples for analysis. This survey aims to refine geological understanding and priori...
NEOS offers three ETFs—Russell 2000 High Income, Real Estate High Income, and Enhanced Income 1-3 Month T-Bill—that combine traditional asset exposure with options overlays to boost distributions. These ETFs deliver yields from about 5% to 13%, with ...
Ethereum (ETH) is trading tightly around $1,915, showing little price movement but important structural signals. The price is consolidating just below $2,000, a level that previously led to a sharp decline, suggesting risk of a drop to $1,300 if supp...
Grey Matters Health has signed an agreement with ProScan Reading Services to interpret brain PET scans at its upcoming NovaScan Neuroimaging Clinic in Davie, Florida, expected to open by September 30. The clinic will use ProScan’s board-certified neu...
